Dental Cleaning to Prevent Graft-Versus-Host Disease
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether professional dental cleaning after a stem cell transplant can help prevent chronic graft-versus-host disease (GVHD), a condition where transplanted immune cells attack your body. You'll receive dental cleanings and be followed for one year to see if this simple preventive step reduces GVHD complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You had a stem cell or bone marrow transplant from an unrelated donor (matched at 9 or 10 out of 10 markers) or from cord blood
- You still have your own teeth (not completely without teeth)
- You did not receive certain GVHD prevention drugs: post-transplant cyclophosphamide, ruxolitinib, or anti-thymocyte globulin in your conditioning
- You can travel to Fred Hutchinson Cancer Center for a follow-up visit one year after enrollment
- You are able to understand and sign consent forms (or have a legal representative do so)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at special immune cells in the body that may be involved in graft-versus-host disease (GVHD), a complication after a stem cell transplant. The goal is to better understand these cells to improve future treatments for GVHD.
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
This study looks at immune cells in tissues affected by chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant. It aims to better understand the condition, which may lead to better treatments.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Hear when a new Chronic Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.